The Dtudy Of SGLT-2 Inhibitor In Patients With Type 2 Diabetes Cardiovascular Risk Factors In Clinical Application

Objective By using noninvasive cardiac function and ultrasonic cardiogram to exceed of joint exploration SGLT-2 inhibitor of column net for type 2 diabetes mellitus patients with cardiovascular risk factors of cardiovascular protection,and discusses the correlation of noninvasive cardiac function and ultrasonic cardiogram to exceed.Methods This study selected the October 2020-October 2021 in type 2 diabetes in the second people’s hospital in hefei for cross-sectional study of 122 patients with cardiovascular risk factors.All patients stable current hypoglycemic scheme 24 weeks or more,all into the group of patients with general information collection（including FPG,P2 h BG,Hb A1 C,blood pressure,blood lipid and body mass index,etc.）,and according to the patients with hypoglycemic solution at present,all the patients divided into Dapagliflozin group,the DPP-IV inhibitors group and the control group,comparison between the three groups of blood sugar,blood lipid,body mass index,the difference of the general information such as;Statistical analysis between the three groups of related cardiac function indexes,such as ejection fraction（EF）,carotid intima thickness,the stroke volume（SV）,cardiac output（CO）,cardiac index（CI）,systemic vascular resistance index（SVRI）,left cardiac work index（LCWI）,and use the Pearson correlation coefficient analysis the correlation of noninvasive cardiac function and heart colour to exceed.Results 1.This study participants included 122 patients with type 2 diabetes,which amounted to Dapagliflozin group 36 cases,DPP-IV inhibitors group 33 cases,control group 61 cases.Comparison between the three groups,the P2 h BG of Dapagliflozin group significantly lower than that of control group（p < 0.05）,compared with the DPP-group IV inhibitors,P2 h BG also decreased,but there was no statistically significant difference（p > 0.05）.Up to Dapagliflozin and DPP-IV inhibitors group,FPG and Hb A1 c levels were lower than the control group,but there was no statistically significant difference（p > 0.05）.2.The three groups of baseline cardiovascular risk factor data comparison,blood pressure（SBP and DBP）,body mass index(BMI,blood lipid（TG,TC,HDL-C,LDL-C）and other indicators are no statistical significance（p > 0.05）.3.Between the three groups of related kidney index comparison,compared with the DPP-IV inhibitors group,urine trace albumin of Dapagliflozin group significantly reduced（p < 0.05）;Compared with the control group,too,fell,but there was no statistically significant difference（p > 0.05）.Comparison between the three groups,in the creatinine,e GFR,uric acid,UACR and other indexes,no statistically significant difference were observed（p > 0.05）.4.The related parameters of cardiac function,between the three groups of column,the SV,SVI,LCWI of Dapagliflozin group were significantly greater than the control group（p < 0.05）,and the DPP-IV inhibitors set SV was also significantly greater than the control group（p < 0.05）,but of Dapagliflozin group compared with the DPP-IV inhibitors group there was no statistically significant difference（p > 0.05）;Dapagliflozin group in the CO,VET were significantly greater than the DPP-IV inhibitors group（p < 0.05）,there was no statistically significant difference compared with the control group（p >0.05）.Dapagliflozin group of CI significantly greater than the DPP-IV inhibitors group and control group（p < 0.05）;Dapagliflozin group of SVRI is significantly less than the DPP IV inhibitors group（p < 0.05）,but there was no significant difference compared with control group（p > 0.05）.Comparison between the three groups,ultrasonic cardiogram to exceed the relevant indicators（such as AO,LA,the LVs,LVd,LVPW,EF,etc.）,carotid artery middle membrane thickness,EDFR,difference has no statistical significance（p > 0.05）.5.Noninvasive cardiac function and ultrasonic cardiogram to exceed the correlation analysis showed that LVd is associated with CI was significantly（p < 0.05）,and a negative correlation;LA was associated significantly with EDFR（p < 0.05）,were positively correlated.Other ultrasonic cardiogram related indicators associated with noninvasive cardiac function indexes had no significant correlation（p > 0.05）.Conclusions 1.The SGLT-2 inhibitor of dapagliflozin can significantly reduce the2-hour postprandial blood glucose level.2.Dapagliflozin can increase net in patients with type 2 diabetes cardiovascular risk factors of myocardial contraction force and ejection ability,reduce the load before and after the heart,for type 2 diabetes mellitus patients with cardiovascular risk factors of cardiovascular protection.3.Noninvasive cardiac function and ultrasonic cardiogram to exceed a certain correlation,and can reflect the early cardiac function in patients with diabetes.